Does autonomous macrophage-driven inflammation promote alveolar damage in COVID-19?
- PMID: 36028257
- PMCID: PMC9411729
- DOI: 10.1183/13993003.01521-2022
Does autonomous macrophage-driven inflammation promote alveolar damage in COVID-19?
Abstract
SARS-CoV-2 has caused devastating effects with over 550 million infections by July 2022 and approximately 6.4 million deaths [1]. Societal and economic impacts will reverberate for years, with continuous evolution of SARS-CoV-2 as it persistently spreads through the human population as exemplified by reduced activity of vaccines and monoclonals against Omicron BA.4 or BA.5 subvariants [2]. A greater understanding of pathogenesis and more tailored therapeutic approaches are therefore essential.
Conflict of interest statement
Conflict of interest: D.H. Dockrell reports past lecture honoraria and travel support from ViiV Healthcare and has received GSK compounds for research purposes, outside the submitted work; and acts as Commissioner for Human Medicines (MHRA) UK. B. McHugh has received GSK compounds for research purposes, outside the submitted work. All other authors have nothing to disclose.
Figures
Comment on
-
Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages.Eur Respir J. 2022 Dec 1;60(6):2102725. doi: 10.1183/13993003.02725-2021. Print 2022 Dec. Eur Respir J. 2022. PMID: 35728978 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous